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Summary
Commercial availability of more than one inhaled antibiotic for the management of
chronic Pseudomonas aeruginosa lung infections in persons with cystic ﬁbrosis creates
a welcome question: Can different inhaled therapies be combined to improve patient
outcomes? Although clinicians intuit that antibiotic alternation might extend the duration
of beneﬁt, prospective clinical trials will be unable to test this hypothesis. Rather,
endpoints acceptable for demonstrating the efﬁcacy of a chronic pulmonary therapy
(lung function improvement/stabilization, reduction in exacerbation risk, improvement
in quality of life) can test only whether the beneﬁt amplitude is increased during ﬁxed
treatment periods. Reduction in pulmonary exacerbation risk appears to be best suited
for this task, although lack of consensus on an objective deﬁnition of exacerbation
independent of the decision to treat is a shortcoming. The broader clinical question of
whether a patient has become refractory to a chronic therapy over time would be better
addressed with a carefully conducted withdrawal study.
© 2011 Elsevier Ltd. All rights reserved.
Introduction
We have entered a new era with respect to inhaled antibiotic
therapies for the management of chronic Pseudomonas
aeruginosa cystic ﬁbrosis (CF) lung infections. Members of
two different antipseudomonal antibiotic classes – amino-
glycosides and monobactams – have now been formulated
speciﬁcally for inhalation and studied extensively in large,
controlled clinical trials.1–7 The commercial availability of
these agents and the potential for future approval of others8
create a welcome challenge for the treating clinician:
how to select the “best” chronic treatment regimen for
an individual patient when presented with a variety of
options. Complexity of choice is not limited to which inhaled
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monotherapy might be best for a particular patient,9,10 but
includes the possibility that more than one class of inhaled
antibiotic might be used in combination to produce a better
effect. How will we leverage our knowledge of clinical
outcome variables to evaluate different treatment regimens
and identify those that are “optimal” for the treatment of
CF pulmonary infections?
In the best of worlds, clinicians would be able to rely
on objective evidence from randomized, controlled clinical
trials that compare different treatment combinations, in
order to choose “superior” regimens. However, even the
“simplest” comparisons of different regimens will prove
difﬁcult and resource-intensive; it may be unrealistic to
assume that comprehensive results from randomized trials
will ever be available to support these decisions. Nonethe-
less, it can be instructive to consider what clinical trial
endpoints and designs might be best suited to randomized
trials of inhaled antibiotic combinations, and the extent to
which trials that utilize these outcomes might help to inform
inhaled antibiotic treatment choices in the future.
0954-6111$ – see front matter © 2011 Elsevier Ltd. All rights reserved.
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Clinical trial designs
For studies of different inhaled antibiotic regimens, it
can be assumed that active (as opposed to placebo)
comparators will be used and that statistical tests will be
of superiority. Investigators will be required to predict a
difference in outcome among active treatment groups that,
if observed, would be accepted as “clinically meaningful”
in order to determine adequate sample sizes to attain
acceptable power. Although this seems relatively simple,
it is not. In the past, studies have tended to focus on
the statistical signiﬁcance of treatment effects compared
with placebo, as opposed to whether thresholds exist
that deﬁne clinically meaningful differences for a given
endpoint, with the notable exception being the Respiratory
Domain of the Cystic Fibrosis Questionnaire-Revised.11 Use
of active comparators will likely translate into relatively
smaller outcome differences among treatment arms than
have been observed for placebo-controlled studies, placing
a premium on endpoints with lower variances in order
to achieve adequate power and manageable sample sizes.
Additionally, these studies will be virtually impossible to
blind, since different inhaled antibiotics have identiﬁable
packaging, formulation, and associated delivery devices;
extended double-blind, double-dummy studies of multiple
inhaled antibiotics would be both extremely costly and very
difﬁcult to enroll. The potential for introduction of bias
in open-label designs is high, and selection of objective
endpoints that are less prone to bias is desirable.
Although a variety of regimens and treatment durations
might be studied in a prospective trial, the simplest, most
frequently discussed regimen is antibiotic alternation, in
which the current 28-day on/off use of an inhaled antibiotic
(“A” periods of Fig. 1) is supplemented by treatment with a
second inhaled antibiotic during 28-day “off-drug” periods
(“B” periods of Fig. 1). Although simple enough to describe,
results from a randomized comparison of “standard of care”
(in which subjects are treated only during “A” periods of
Fig. 1) with antibiotic alternation (where different inhaled
antibiotics are administered during “A” and “B” periods
of Fig. 1) would raise questions for clinicians. Consider
that such a design is both a comparison of monotherapy
vs combination therapy and of intermittent vs continuous
treatment. Superior efﬁcacy associated with a combination
regimen could not be unambiguously attributed either
to use of multiple inhaled antibiotics or to continuous
B1
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Fig. 1. Inhaled antibiotic study design template. Basic chronic-
intermittent treatment design used for past inhaled antibiotic stud-
ies. Tobramycin inhalation solution (TIS) approval was supported by
studies in which subjects were randomized to receive 4 weeks of
either active or placebo treatment (“An”; gray boxes) interspersed
with 4-week rest periods (“Bn”; white boxes).1 Open-label studies
of TIS,2,10,12,13 aztreonam for inhalation solution (AZLI),10,14 and
tobramycin inhalation powder (TIP)13 have all used this design, with
subjects receiving active treatment during “A” periods of 4 weeks
and rest during “B” periods of 4 weeks.
(as opposed to intermittent) treatment. Assurance that
antibiotic alternation (as opposed to continuous treatment)
was responsible for an observed beneﬁt would require two
additional comparator groups, each receiving one of the two
inhaled antibiotics as continuous monotherapy. Such a four-
armed study design would be complex, costly, and unlikely
to garner much enthusiasm in the CF community.
Treatment outcomes
An underlying assumption in the hypothesized superiority
of combination inhaled antibiotic therapy over mono-
therapy is that combining multiple antibiotic classes may
delay or slow selection for bacterial opportunists with
reduced susceptibility to either antibiotic. In this scenario,
infecting bacterial populations would remain relatively
more susceptible to antibiotics, and therefore antibiotics
should continue to provide beneﬁt for longer periods of
time.15 Although few data are available to support such
a hypothesis, it may ultimately prove to be correct over
years of cumulative antibiotic exposure. Proponents of
this line of reasoning might argue that differences in in
vitro antibiotic susceptibilities of bacterial isolates at the
end of a randomized study would be a valid surrogate
endpoint for efﬁcacy. However, there are several problems
with this approach. First, extended studies of intermittent
monotherapies suggest that the rate of emergence of
bacterial isolates with reduced antibiotic susceptibility is
relatively modest over time frames likely to be covered
in a prospective study,10,14–17 leaving little margin for
“superiority” (i.e., less emergence of isolates with reduced
susceptibilities) associated with combination antibiotic
therapy. Perhaps, more importantly, in vitro antibiotic
susceptibility has not proven to be predictive of inhaled
antibiotic response9,17 nor has change in bacterial density
itself (Fig. 2).1,9,10,18
Four endpoints of note have been incorporated into
past inhaled antibiotic trials: (1) sustained difference in
forced expiratory volume in 1 second (FEV1)1,3–6,9,10,13,19,20;
(2) difference in mean rate of FEV1 decline2,21; (3) difference
in risk for pulmonary exacerbation1,2,5; and (4) difference
in patient-reported quality of life (QoL; Table 1).5,7,10 Each
of these outcomes has associated strengths and weaknesses
when considered as candidates for a primary clinical trial
endpoint.
An advantage of FEV1 difference as an endpoint is
that sample size requirements are relatively smaller than
those needed to detect a difference in risk for pulmonary
exacerbation. This is particularly true when variance is
reduced by measuring age-, height-, sex-adjusted FEV1 (in
liters), rather than FEV1 % predicted.22 However, difference
in FEV1 is a cross-sectional measure that may not capture
the potential cumulative beneﬁt of more intense treatment
resulting from antibiotic alteration. For example, difference
in mean FEV1 at t6 in Fig. 1 as an endpoint would be unlikely
to distinguish between treatment with alternating inhaled
antibiotics in each A and B period of Fig. 1, and treatment
with the second inhaled antibiotic only in period B3 of
Fig. 1. A more fundamental problem with sustained FEV1
difference as an endpoint is interpretation of its clinical
meaning. The rate at which FEV1 declines (a different FEV1
measure) has been proposed as a meaningful predictor of
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Fig. 2. Change in P. aeruginosa sputum density and pulmonary function at week 4 of the inhaled tobramycin studies. Subjects
receiving tobramycin inhalation solution (closed diamonds) had a lower mean sputum bacterial density and a higher mean pulmonary
function than did those receiving placebo (open diamonds) at the end of week 4.1,18 However, change in bacterial density was a poor
predictor of change in pulmonary function in individual subjects. CFU, colony-forming unit; FEV1, forced expiratory volume in 1 second;
TIS, tobramycin inhaled solution.
Table 1
Endpoints used in inhaled antibiotic trials: strengths and weaknesses
Outcome Requirement
Sample size Duration
Measure type Inhaled antibiotic Study precedents
FEV1 difference + + Cross-sectional 1,3–6,9,10,13,19,20
FEV1 rate of decline ++ ++++ Cumulative 2,21
Risk for pulmonary exacerbation +++ ++ Cumulative 1,2,5
Difference in QoL + + Cross-sectional 5,7,10
The relative strength or weakness of each outcome measure as a study endpoint is reﬂected by the number of + signs. The greater the
number of + signs, the greater the relative weakness of the endpoint.
survival,23,24 but two chronic CF therapies shown to slow
lung function decline – high-dose ibuprofen and inhaled
corticosteroids – do not produce a sustained improvement in
FEV1.25–28 Thus, treatments that slow lung function decline
do not necessarily produce sustained improvements in FEV1,
and agents that improve FEV1 may not necessarily slow the
rate of FEV1 decline. Although an argument has been made
for the clinical relevance of FEV1 decline as an endpoint,23,24
this endpoint requires studies of such extended duration29
that they would probably be unfeasible. In addition, it is
not clear what magnitude of difference in mean decline rate
would be accepted as clinically meaningful.
Difference in patient-reported QoL between treatment
groups has potential as a study endpoint, although QoL
difference is also a cross-sectional measure. Data collected
at study completion (t6 of Fig. 1) would presumably miss
any cumulative beneﬁt of more intensive therapy during the
study. In order to address this problem, investigators would
have to consider averaging QoL across all study visits. The
question of whether an improved average QoL is the result
of continuous therapy, combination therapy, or both would
remain without adequate controls.
The endpoint that may resonate equally with clinicians
and regulators is difference in risk for pulmonary exacerba-
tion. Exacerbation risk is a clinically relevant endpoint that
has been important for the regulatory approval of inhaled
antibiotics in the past, and one that could presumably
capture the cumulative effect of more intense antibiotic
therapy across a study period. Pulmonary exacerbation risk
also lends itself well to pharmacoeconomic analyses, since
exacerbations are resource-intensive events.30,31 However,
lack of agreement on an objective deﬁnition of exacerbation
that does not rely on a clinician’s decision to treat is
currently a shortcoming of this endpoint.32
Arguments have been made for studying treatment-
related differences in pathophysiologic markers of CF
lung disease, including mucociliary clearance,33,34 lung
clearance index measured by multiple breath washout,35–37
airway anatomy measured by high-resolution computerized
tomography,38,39 and inﬂammation in induced sputum.40,41
However, no data are currently available with which to
correlate a treatment-associated difference in any these
markers of CF lung pathophysiology with a subsequent
clinical response.
Applying study results to clinical care
Randomized trials of inhaled antibiotic combinations are
unlikely to exceed 1 year in duration – well short of the
duration an individual patient can expect to beneﬁt from
inhaled antibiotics. These ﬁxed-duration studies will test
for evidence of increased amplitude of beneﬁt associated
with increased antibiotic intensity. It may be, however,
that clinician perception of the potential for beneﬁt of
combining inhaled antibiotics is related to longitudinal
extension of inhaled antibiotic treatment response rather
than to increased beneﬁt within a single year of treatment.
For this reason, inability to detect a difference in treatment-
associated beneﬁt in a single year may not dissuade
clinicians from the belief that inhaled antibiotic rotation
will ultimately prove beneﬁcial.
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Fig. 3. Theoretical response proﬁles for inhaled antibiotics.
Theoretical response (undeﬁned) is plotted on the y-axis for each
unit of inhaled antibiotic treatment (x-axis) for a patient. Overall
response to an antibiotic can be expressed as total area (response x
time). Panel A depicts continuous inhaled antibiotic monotherapy to
which a patient becomes refractory during the observation period.
Panel B illustrates intermittent inhaled antibiotic monotherapy in
which efﬁcacy is retained at the end of the observation period.
Overall response (response × time) in Panel B is greater than that
in Panel A. Panel C shows sequential continuous monotherapy with
two different inhaled antibiotics, which are represented by gray
and white bars. Panel D displays continuous alternating therapy
with two different inhaled antibiotics, which are represented by
gray and white bars. Total response (response × time) in Panel D is
greater than that in Panel C.
The hypothesis that rotating inhaled antibiotics can
increase total patient beneﬁt over a lifetime will likely
remain untested until retrospective, comparative effective-
ness analyses of patient registry data are conducted years
from now. However, assumptions underlying this hypothesis
seem logical. For example, it is reasonable to assume that
the total beneﬁt an inhaled antibiotic can provide to a
given patient is ﬁnite and that at some point the patient
will become refractory to further antibiotic treatment (i.e.,
administration of that antibiotic is not associated with
any additional beneﬁt; Fig. 3A). It also seems reasonable
that the time period over which an inhaled antibiotic
retains its effectiveness can be inﬂuenced by the dosing
regimens used. This is the underlying tenet of intermittent
inhaled tobramycin delivery: Continuous inhaled tobramycin
treatment for 3 months showed decreasing FEV1 beneﬁt
after the ﬁrst month of therapy,18 whereas intermittent
inhaled tobramycin treatment provided continued beneﬁt
after 6 months1 and 2 years.12 Although this construct has
never been objectively tested in a single study and these
historical studies differ in important ways (e.g., dose, dosing
schedule, delivery device, sample size), the concept may
nonetheless be true (panels A and B of Fig. 3). If one were
to extend this reasoning, a potential beneﬁt of alternating
inhaled antibiotic classes would be increasing the net period
Time
study
“A” monotherapy “A”– B” alternation“
antibiotic “A”
response
Fig. 4. Theoretical comparison of response to extended
treatment with inhaled antibiotics. Response (undeﬁned; y-axis)
to inhaled antibiotic “A” treatment is plotted over axis time when
“A” is administered as a monotherapy (black line) or as part of
an alternating inhaled antibiotic regimen. Total beneﬁt can be
expressed as the area under the curve (response × time). The time
frame over which alternation of inhaled antibiotics may provide an
advantage over monotherapy may be much longer than that covered
by a randomized study (gray box) comparing treatment regimens.
of effectiveness for each antibiotic relative to the periods of
effectiveness that would be realized if each antibiotic were
administered sequentially as monotherapy (panels C and D
of Fig. 3). Extension of the effective life of each inhaled
antibiotic would presumably play out over the course of
years or even decades of a patient’s life, and would be
unlikely to be captured by the endpoints considered in 6- to
12-month randomized trials (Fig. 4). If the true promise
of inhaled antibiotic rotation lies in delaying the time at
which a patient becomes refractory to all available inhaled
antibiotic therapies, then we have yet to consider a clinical
trial endpoint likely to capture that beneﬁt. Shorter-term
endpoints may justify or encourage combination antibiotic
use by clinicians, but they will not allow us to answer this
greater question: Have we increased the effective time span
in which we can treat patients?
Testing for refractoriness in patients
If it is true that patients will ultimately become refractory
to inhaled antibiotics and that the time course of this
phenomenon can be affected by the manipulation of
treatment regimens, it follows that clinicians should be
seeking evidence that patients have become refractory
to inhaled antibiotic regimens they have received for
extended time periods. When an individual becomes
refractory to a chronic therapy to which he or she had
previously responded, treatment cessation should not result
in immediate clinical deterioration. Switching a patient from
an “old” chronic therapeutic regimen to a “new” regimen
(or at least one that has not been used for an extended
period) may result in an improvement in clinical status –
a circumstance consistent with improved efﬁcacy of the new
regimen, but not proof that the prior regimen was no longer
effective. Such a conclusion requires withdrawal of therapy
and careful evaluation.
It would be impossible to determine if a patient has
become refractory to a treatment regimen based on
some of the efﬁcacy endpoints discussed above. For
example, a clinician could not detect a change in risk
for pulmonary exacerbation in an individual subject over
a short observation period or whether FEV1 rate of
decline has been inﬂuenced by treatment cessation. These
cumulative measures do not lend themselves to such
short-term assessments. On the other hand, it would be
relatively simple to assess an immediate change in either
FEV1 % predicted or patient-reported QoL in an individual
following cessation of a chronic therapy. Given that some
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uncertainty exists regarding the clinical meaning of modest
changes in FEV1, perhaps change in QoL is the more relevant
measure to follow at treatment discontinuation. Carefully
conducted withdrawal studies may be the only reliable
method for determining that a patient is no longer beneﬁting
from a chronic treatment regimen.
Conclusion
Prospective, randomized studies of the safety and efﬁcacy
of combining inhaled antibiotics are feasible. Endpoints
that collect data in a cumulative fashion are best suited
to detecting superiority in response to a more intensive
treatment regimen. These studies will necessarily test
the hypothesis that a given intervention provides greater
amplitude of beneﬁt (with acceptable safety proﬁles) over
a ﬁxed time period. Although this information will be
useful, it may not address the underlying motivations (and
the greatest potential beneﬁts) of combining therapies:
extension of the effective time during which infections can
be suppressed with inhaled antibiotics. It will be the job of
care providers to consider whether patients under their care
continue to beneﬁt from inhaled antibiotics (alternated or
not) after months or years of use. They may wish to consider
careful and deliberate N-of-1 “withdrawal studies” to assess
refractoriness, and to record these data in a manner that
will allow for future characterization of outcomes at the
population level using retrospective, observational analyses.
Cross-sectional efﬁcacy endpoints may be better suited to
this task.
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